These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34857046)

  • 1. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    Alzheimers Res Ther; 2021 Dec; 13(1):197. PubMed ID: 34857046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.
    Kim WJ; Noh JH; Han K; Park CY
    J Alzheimers Dis; 2021; 81(3):1263-1272. PubMed ID: 33935082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.
    Tian S; Jiang J; Wang J; Zhang Z; Miao Y; Ji X; Bi Y
    Diabetes Metab Res Rev; 2023 Oct; 39(7):e3673. PubMed ID: 37302139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
    Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
    Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
    Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
    Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2022; 86(1):245-257. PubMed ID: 35034902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
    Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
    J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan.
    Ou HT; Chang KC; Liu YM; Wu JS
    J Diabetes; 2017 Mar; 9(3):256-266. PubMed ID: 27062145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
    PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
    Hong JL; Buse JB; Jonsson Funk M; Pate V; Stürmer T
    Diabetes Care; 2018 Jun; 41(6):1196-1203. PubMed ID: 29618573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.